

Anti-Complement C5 Antibody (Crovalimab)

Introduction

Crovalimab (SKY59; RO7112689) is a humanized antibody against C5 in a pH-dependent manner with KD of 15.2nM and 16.8 μ M at pH 7.4 and 5.8, respectively. Crovalimab binds to human FcRn with high affinity (KD: 17 μ M; pH 6.0). Crovalimab blocks the cleavage of C5 by C5 convertase and inhibits the activity of a C5 variant (p.Arg885His). Crovalimab significantly inhibits the formation of C5b-9 in all three complement pathways, the classical pathway (CP), the lectin pathway (LP), and the alternative pathway (AP). Crovalimab has the potential to be used in the study of paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases.

Product parameters

Alternative Names	SKY59, RG6107, RO7112689
Target Accession	P01031
Target	Complement C5
CAS number	
Molecular Weight	145 kDa
Host	СНО
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	lgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years

Note

Note





1. This product is for scientific research use only.









APExBIO Technology www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com